1ILMN Stock Chart & Stats
€196.52
-€0.98(-0.57%)
At close: 4:00 PM EDT
€196.52
-€0.98(-0.57%)
Day’s Range― - ―
52-Week Range€49.00 - €284.00
Previous CloseN/A
Volume0.00
Average Volume (3M)69.00
Market Cap
€37.46B
Enterprise Value€28.37B
Total Cash (Recent Filing)€1.17B
Total Debt (Recent Filing)€2.53B
Price to Earnings (P/E)51.4
Beta0.39
Next Earnings
Oct 29, 2026EPS Estimate
1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.41
Shares Outstanding151,000,000
10 Day Avg. Volume186
30 Day Avg. Volume69
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)7.65
Price to Sales (P/S)4.81
P/FCF Ratio22.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€207.73Price Target Upside5.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)4.78
Revenue Forecast (FY)€4.13B
Bulls Say, Bears Say
Bulls Say
NovaSeq X Installed-base Expansion Supports Recurring Consumables DemandContinued NovaSeq X placements expand Illumina’s installed base and create a durable opportunity for recurring sequencing-consumables revenue. The growing clinical footprint and expected pull-through into 2027 can improve utilization, deepen customer relationships, and support longer-term revenue visibility.
Strong Profitability And Cash GenerationHigh gross and operating margins, combined with substantial operating and free cash flow, demonstrate meaningful earnings power in the current recovery. This financial capacity can fund research, product development, customer support, debt service, and shareholder returns without relying solely on external capital.
Broadening Growth Across Clinical Sequencing And Adjacent ProgramsGrowth in clinical consumables and service revenue is complemented by new spatial and minimal-residual-disease workflows, broadening Illumina’s genomic-analysis platform. Greater clinical adoption and additional applications can diversify demand and increase the value of its instruments, software, and consumables ecosystem.
Bears Say
Research And Applied Consumables Remain Structurally WeakPersistent weakness in research consumables indicates that part of Illumina’s customer base remains constrained, limiting the benefit of stronger clinical demand. If research funding and purchasing remain cautious, lower instrument utilization can reduce recurring consumables revenue and delay a broader recovery.
Leverage And Refinancing Reduce Financial FlexibilityModerate-to-elevated leverage leaves Illumina less flexible if earnings weaken again, particularly after the earlier period of losses. Refinancing extends maturities, but debt obligations and interest costs still compete with investment and shareholder-return priorities during a slower operating cycle.
Earnings Durability Remains Uncertain After Prior Losses And Uneven DemandThe sharp swing from losses to strong current profitability shows meaningful execution progress but also a history of unstable earnings. Ongoing research weakness, regional variability, and cost pressure could make margins and cash conversion less predictable, challenging the durability of the recovery.
Illumina News
1ILMN FAQ
What was Illumina’s price range in the past 12 months?
Illumina lowest stock price was €49.00 and its highest was €284.00 in the past 12 months.
What is Illumina’s market cap?
Illumina’s market cap is €37.46B.
When is Illumina’s upcoming earnings report date?
Illumina’s upcoming earnings report date is Oct 29, 2026 which is in 16 days.
How were Illumina’s earnings last quarter?
Illumina released its earnings results on Jul 30, 2026. The company reported €1.173 earnings per share for the quarter, beating the consensus estimate of €1.098 by €0.075.
Is Illumina overvalued?
According to Wall Street analysts Illumina’s price is currently Undervalued.
Does Illumina pay dividends?
Illumina does not currently pay dividends.
What is Illumina’s EPS estimate?
Illumina’s EPS estimate is 1.22.
How many shares outstanding does Illumina have?
Illumina has 151,000,000 shares outstanding.
What happened to Illumina’s price movement after its last earnings report?
Illumina reported an EPS of €1.173 in its last earnings report, beating expectations of €1.098. Following the earnings report the stock price went down -1.695%.
Which hedge fund is a major shareholder of Illumina?
Currently, no hedge funds are holding shares in IT:1ILMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Illumina Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€207.73 (5.71% Upside)
€207.73 (5.71% Upside)
Blogger Sentiment
Neutral
IT:1ILMN Sentiment 58%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth €388.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
188.40%
12-Months-Change
Fundamentals
Return on Equity
31.08%
Trailing 12-Months
Asset Growth
9.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Illumina
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
1ILMN Company Deck
1ILMN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: Illumina delivered a quarter with strong top-line beats, materially higher instrument placements (especially NovaSeq X), margin outperformance, raised full-year guidance and strengthened multi-omics and BioInsight momentum (Billion Cell Atlas revenue and partners). Headwinds remain—memory and freight costs, inventory/tax timing impacts, and continued weakness in research consumables and some regions—but management has absorbed costs, secured supply, and raised guidance while reaffirming long-term targets. The positive operational and financial beats and the upgraded outlook outweigh the listed challenges.View all IT:1ILMN earnings summaries1ILMN Revenue Breakdown
74.30% Consumables
11.10% Instruments
14.60% Service and other revenue
1ILMN Stock 12 Month Forecast
Average Price Target
€207.73
▲(5.71% Upside)